152 related articles for article (PubMed ID: 37336082)
1. Design, synthesis, and analgesia evaluation of novel Transient Receptor Potential Vanilloid 1 (TRPV1) agonists modified from Cannabidiol (CBD).
Jin F; Wen Y; Lin G; Yu S; Wang C; Ye W; Zhang J
Bioorg Med Chem; 2023 Jul; 90():117379. PubMed ID: 37336082
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Potent and Selective Transient Receptor Potential Vanilloid 1 (TRPV1) Agonists with Analgesic Effects
Liang Q; Qiao Z; Zhou Q; Xue D; Wang K; Shao L
J Med Chem; 2022 Sep; 65(17):11658-11678. PubMed ID: 36008373
[TBL] [Abstract][Full Text] [Related]
3. Novel piperazine urea derivatives as highly potent transient receptor potential vanilloid 1 (TRPV1) antagonists.
Hu J; Gao M; Zhang Y; Wang Y; Qiao Z; Zhang W; Wang Q; Yan L; Qian H
Bioorg Chem; 2021 Oct; 115():105229. PubMed ID: 34364049
[TBL] [Abstract][Full Text] [Related]
4. Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease.
Crivelaro do Nascimento G; Ferrari DP; Guimaraes FS; Del Bel EA; Bortolanza M; Ferreira-Junior NC
Neuropharmacology; 2020 Feb; 163():107808. PubMed ID: 31706993
[TBL] [Abstract][Full Text] [Related]
5. Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action.
Maione S; Piscitelli F; Gatta L; Vita D; De Petrocellis L; Palazzo E; de Novellis V; Di Marzo V
Br J Pharmacol; 2011 Feb; 162(3):584-96. PubMed ID: 20942863
[TBL] [Abstract][Full Text] [Related]
6. Polypeptide modulators of TRPV1 produce analgesia without hyperthermia.
Andreev YA; Kozlov SA; Korolkova YV; Dyachenko IA; Bondarenko DA; Skobtsov DI; Murashev AN; Kotova PD; Rogachevskaja OA; Kabanova NV; Kolesnikov SS; Grishin EV
Mar Drugs; 2013 Dec; 11(12):5100-15. PubMed ID: 24351908
[TBL] [Abstract][Full Text] [Related]
7. Novel dual-target FAAH and TRPV1 ligands as potential pharmacotherapeutics for pain management.
Qiao Z; Liu S; Zhai W; Jiang L; Ma Y; Zhang Z; Wang B; Shao J; Qian H; Zhao F; Yan L
Eur J Med Chem; 2024 Mar; 267():116208. PubMed ID: 38325006
[TBL] [Abstract][Full Text] [Related]
8. Discovery of first-in-class highly selective TRPV1 antagonists with dual analgesic and hypoglycemic effects.
Liu C; Wang W; Zhao S; Chen S; Chen H; Wang S; Li Z; Qian H; Tian X
Bioorg Med Chem; 2024 Jun; 107():117750. PubMed ID: 38776567
[TBL] [Abstract][Full Text] [Related]
9. Activation of the transient receptor potential vanilloid-1 (TRPV1) channel opens the gate for pain relief.
Jancsó G; Dux M; Oszlács O; Sántha P
Br J Pharmacol; 2008 Dec; 155(8):1139-41. PubMed ID: 18997813
[TBL] [Abstract][Full Text] [Related]
10. A patent review of transient receptor potential vanilloid type 1 modulators (2014-present).
Gao M; Wang Y; Liu L; Qiao Z; Yan L
Expert Opin Ther Pat; 2021 Feb; 31(2):169-187. PubMed ID: 33377418
[No Abstract] [Full Text] [Related]
11. TRPV1-Targeted Drugs in Development for Human Pain Conditions.
Iftinca M; Defaye M; Altier C
Drugs; 2021 Jan; 81(1):7-27. PubMed ID: 33165872
[TBL] [Abstract][Full Text] [Related]
12. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.
Espejo-Porras F; Fernández-Ruiz J; Pertwee RG; Mechoulam R; García C
Neuropharmacology; 2013 Dec; 75():155-63. PubMed ID: 23924692
[TBL] [Abstract][Full Text] [Related]
13. Novel benzodiazepines derivatives as analgesic modulating for Transient receptor potential vanilloid 1.
Liu Y; Liao C; Zhou J; Liu C; Li Q; Jiang Y; Qian H
Bioorg Med Chem; 2018 Aug; 26(15):4567-4573. PubMed ID: 30093345
[TBL] [Abstract][Full Text] [Related]
14. Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity.
García-Martínez C; Fernández-Carvajal A; Valenzuela B; Gomis A; Van Den Nest W; Ferroni S; Carreño C; Belmonte C; Ferrer-Montiel A
J Pain; 2006 Oct; 7(10):735-46. PubMed ID: 17018334
[TBL] [Abstract][Full Text] [Related]
15. Discovery of (S)-N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl)pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist.
Qiao Y; Zhang Y; Qiao Z; He W; Chen Y; Song D; Wang G; Guo N; Shao L; Tian Z; Wang Q; Yan L; Qian H
Eur J Med Chem; 2022 Apr; 233():114191. PubMed ID: 35263708
[TBL] [Abstract][Full Text] [Related]
16. Phenylquinoline transient receptor potential vanilloid 1 antagonists for the treatment of pain: Discovery of 1-(2-phenylquinoline-4-carbonyl)-N-(4-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide.
Liao C; Liu Y; Liu C; Zhou J; Li H; Wang N; Li J; Liu T; Ghaleb H; Huang W; Qian H
Bioorg Med Chem; 2018 Feb; 26(4):845-854. PubMed ID: 29317149
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks.
Wong GY; Gavva NR
Brain Res Rev; 2009 Apr; 60(1):267-77. PubMed ID: 19150372
[TBL] [Abstract][Full Text] [Related]
18. TRPV1: A Common Denominator Mediating Antinociceptive and Antiemetic Effects of Cannabinoids.
Louis-Gray K; Tupal S; Premkumar LS
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077412
[TBL] [Abstract][Full Text] [Related]
19. TRPV1 signaling: mechanistic understanding and therapeutic potential.
Xia R; Samad TA; Btesh J; Jiang LH; Kays I; Stjernborg L; Dekker N
Curr Top Med Chem; 2011; 11(17):2180-91. PubMed ID: 21671876
[TBL] [Abstract][Full Text] [Related]
20. Novel dual-target μ‑opioid and TRPV1 ligands as potential pharmacotherapeutics for pain management.
Gao M; Zhang Y; Wang B; Guo N; Shao L; Zhai W; Jiang L; Wang Q; Qian H; Yan L
Bioorg Chem; 2023 Feb; 131():106335. PubMed ID: 36603243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
